Cargando…
Natural products as LSD1 inhibitors for cancer therapy
Natural products generally fall into the biologically relevant chemical space and always possess novel biological activities, thus making them a rich source of lead compounds for new drug discovery. With the recent technological advances, natural product-based drug discovery is now reaching a new er...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305746/ https://www.ncbi.nlm.nih.gov/pubmed/32837872 http://dx.doi.org/10.1016/j.apsb.2020.06.007 |
_version_ | 1783548528963878912 |
---|---|
author | Fang, Yuan Yang, Chao Yu, Zhiqiang Li, Xiaochuan Mu, Qingchun Liao, Guochao Yu, Bin |
author_facet | Fang, Yuan Yang, Chao Yu, Zhiqiang Li, Xiaochuan Mu, Qingchun Liao, Guochao Yu, Bin |
author_sort | Fang, Yuan |
collection | PubMed |
description | Natural products generally fall into the biologically relevant chemical space and always possess novel biological activities, thus making them a rich source of lead compounds for new drug discovery. With the recent technological advances, natural product-based drug discovery is now reaching a new era. Natural products have also shown promise in epigenetic drug discovery, some of them have advanced into clinical trials or are presently being used in clinic. The histone lysine specific demethylase 1 (LSD1), an important class of histone demethylases, has fundamental roles in the development of various pathological conditions. Targeting LSD1 has been recognized as a promising therapeutic option for cancer treatment. Notably, some natural products with different chemotypes including protoberberine alkaloids, flavones, polyphenols, and cyclic peptides have shown effectiveness against LSD1. These natural products provide novel scaffolds for developing new LSD1 inhibitors. In this review, we mainly discuss the identification of natural LSD1 inhibitors, analysis of the co-crystal structures of LSD1/natural product complex, antitumor activity and their modes of action. We also briefly discuss the challenges faced in this field. We believe this review will provide a landscape of natural LSD1 inhibitors. |
format | Online Article Text |
id | pubmed-7305746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-73057462020-06-22 Natural products as LSD1 inhibitors for cancer therapy Fang, Yuan Yang, Chao Yu, Zhiqiang Li, Xiaochuan Mu, Qingchun Liao, Guochao Yu, Bin Acta Pharm Sin B Review Natural products generally fall into the biologically relevant chemical space and always possess novel biological activities, thus making them a rich source of lead compounds for new drug discovery. With the recent technological advances, natural product-based drug discovery is now reaching a new era. Natural products have also shown promise in epigenetic drug discovery, some of them have advanced into clinical trials or are presently being used in clinic. The histone lysine specific demethylase 1 (LSD1), an important class of histone demethylases, has fundamental roles in the development of various pathological conditions. Targeting LSD1 has been recognized as a promising therapeutic option for cancer treatment. Notably, some natural products with different chemotypes including protoberberine alkaloids, flavones, polyphenols, and cyclic peptides have shown effectiveness against LSD1. These natural products provide novel scaffolds for developing new LSD1 inhibitors. In this review, we mainly discuss the identification of natural LSD1 inhibitors, analysis of the co-crystal structures of LSD1/natural product complex, antitumor activity and their modes of action. We also briefly discuss the challenges faced in this field. We believe this review will provide a landscape of natural LSD1 inhibitors. Elsevier 2021-03 2020-06-20 /pmc/articles/PMC7305746/ /pubmed/32837872 http://dx.doi.org/10.1016/j.apsb.2020.06.007 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Fang, Yuan Yang, Chao Yu, Zhiqiang Li, Xiaochuan Mu, Qingchun Liao, Guochao Yu, Bin Natural products as LSD1 inhibitors for cancer therapy |
title | Natural products as LSD1 inhibitors for cancer therapy |
title_full | Natural products as LSD1 inhibitors for cancer therapy |
title_fullStr | Natural products as LSD1 inhibitors for cancer therapy |
title_full_unstemmed | Natural products as LSD1 inhibitors for cancer therapy |
title_short | Natural products as LSD1 inhibitors for cancer therapy |
title_sort | natural products as lsd1 inhibitors for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305746/ https://www.ncbi.nlm.nih.gov/pubmed/32837872 http://dx.doi.org/10.1016/j.apsb.2020.06.007 |
work_keys_str_mv | AT fangyuan naturalproductsaslsd1inhibitorsforcancertherapy AT yangchao naturalproductsaslsd1inhibitorsforcancertherapy AT yuzhiqiang naturalproductsaslsd1inhibitorsforcancertherapy AT lixiaochuan naturalproductsaslsd1inhibitorsforcancertherapy AT muqingchun naturalproductsaslsd1inhibitorsforcancertherapy AT liaoguochao naturalproductsaslsd1inhibitorsforcancertherapy AT yubin naturalproductsaslsd1inhibitorsforcancertherapy |